Abstract:Background. Chimeric antigen receptor (CAR) T cell therapy, a “living drug” immunotherapy, harnesses the power of T-cells from a patient (autologous) or healthy donor (allogeneic) to target and kill cancer cells and has shown unprecedented outcomes in patients with relapsed and refractory malignancies. Treatment with CAR-T cells requires the application of unique skillsets in recognised specialist centres for successful outcomes and requires management by the multidisciplinary team incorporating the specialist pharmacist. Method. A multimodal research strategy was employed for this literature review whereby PubMed, Google Scholar, Embase, Stella Library Search, EMA website, and EBMT website were sources of information. The search was limited from 2020 onwards with key terms referring to CAR-T cell therapy. Results and Discussion. There are six CAR-T cell products currently approved by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) which target haematological malignancies with abundant clinical trials underway exploring new and improved CAR designs and antigen targets. As CAR-T cell therapy is an advanced therapy medicinal product (ATMP), there is need for an extensive regulatory framework underpinning its safety and efficacy. The clinical pharmacist plays an integral role in the provision of safe and effective CAR-T cell therapy including governance, operational and clinical aspects of treatment. Pharmacists may also be involved through provision of “Qualified Person” (QP) expertise in clinical trials and for release within hospitals under certain circumstances. There is a need for harmonised and accessible guidance on the clinical delivery of ATMPs such as CAR-T cells, with fully delineated responsibilities of pharmacists involving the oversight and supervision of CAR-T cell treatment. Conclusion. There is an unmet need to provide suitable and applicable literature for clinical pharmacists who are involved in the delivery of CAR-T cells. We have provided an overview of T-cell biology and an explanation of CAR-T cell design and the biomanufacturing process. We reviewed the complex and multifaceted treatment cycle requiring considerable logistics, and described the involvement of the clinical pharmacist in each part of this cycle from patient selection to postinfusion care. Finally, we look to the challenges and future opportunities that will require the involvement of the clinical pharmacist.

Chimeric antigen receptor (CAR) T-cell therapy: an overview for nurses

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

CAR T-cell therapy in cancer: Integrating nursing perspectives for enhanced patient care

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review

Nursing management for adult recipients of CAR T-19 therapy

Chimeric Antigen Receptor-T (CAR-T) Cells as “Living Drugs”: A Clinical Pharmacist Perspective

CAR T-cell immunotherapy: The path from the by-road to the freeway?

Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges

Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice

Educating Multidisciplinary Care Teams, Patients, and Caregivers on CAR T-Cell Therapy

[Chimeric antigen receptors in oncology: clinical applications and new developments]

Chimeric antigen receptor T-cell therapy for the community oncologist

From bench to bedside: the history and progress of CAR T cell therapy

CAR T-cell immunotherapy of B-cell malignancy: the story so far

Nursing Management in Pediatric Patients Undergoing Chimeric Antigen Receptor T (CAR-T) Cell Therapy: A Systematic Literature Review

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion

Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy

Advances and challenges in chimeric antigen receptor‐natural killer cell immunotherapy for cancer